Raymond James & Associates’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Raymond James & Associates’s Portfolio IDXG Stock Details IDXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-2,000	Closed	-$10K	–	3847
2019 Q4	$10K	Hold	2,000	–	–	﹤0.01%	3635
2019 Q3	$16K	Hold	2,000	–	–	﹤0.01%	3551
2019 Q2	$15K	Hold	2,000	–	–	﹤0.01%	3569
2019 Q1	$16K	Hold	2,000	–	–	﹤0.01%	3545
2018 Q4	$16K	Hold	2,000	–	–	﹤0.01%	3450
2018 Q3	$31K	Hold	2,000	–	–	﹤0.01%	3523
2018 Q2	$18K	Hold	2,000	–	–	﹤0.01%	3505
2018 Q1	$18K	Hold	2,000	–	–	﹤0.01%	3388
2017 Q4	$20K	Hold	2,000	–	–	﹤0.01%	3341
2017 Q3	$31K	Hold	2,000	–	–	﹤0.01%	3279
2017 Q2	$18K	Buy	2,000 +720	+56%	+$14.1K	﹤0.01%	3264
2017 Q1	$34K	Buy	+1,280	New	+$45.8K	﹤0.01%	3173

Other funds holding IDXG

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Raymond James & Associates's IDXG Position: Q1 2020 in Review

Raymond James & Associates sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q1 2020, closing a stake of 2,000 shares — an estimated $10K sold.

Raymond James & Associates first reported a position in IDXG in Q1 2017 and held it in 12 quarters. The position peaked at $34K in Q1 2017. 15 funds tracked by Wall St. Rank hold IDXG as of Q1 2020.

Raymond James & Associates reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Raymond James & Associates sold 2,000 Interpace Biosciences, Inc. Common Stock shares in Q1 2020, an estimated $10K.
Raymond James & Associates first reported a position in Interpace Biosciences, Inc. Common Stock in Q1 2017 and held it in 12 quarters.
Raymond James & Associates's Interpace Biosciences, Inc. Common Stock position peaked at $34K in Q1 2017.
15 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q1 2020.

Based on Raymond James & Associates's 13F filing for Q1 2020, filed 21 Apr 2020.